Redhill Biopharma - ADR

+0.12 (+1.96%)

Redhill Biopharma Announces Positive Top-Line Safety And Efficacy Data From Phase 2 COVID-19 Study Of Opaganib

Published: 12/31/2020 19:27 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma Announces Positive Top-line Safety and Efficacy Data From Phase 2 Covid-19 Study of Opaganib.
Redhill Biopharma Ltd - Top-line Data From Global Phase 2/3 Covid-19 Study in 270 Hospitalized Patients Expected Q1/2021.
Redhill Biopharma Ltd - Interim Dsmb Futility Analysis is Expected in Coming Weeks.
Redhill Biopharma - Prelim Data From Study Shows Orally-administered Opaganib Was Safe, With No Material Safety Differences Between Opaganib, Control Arms.